Editorial board disclosure policy

(Last updated March 2022)
All editors responsible for recommending or making publication decisions are requested to disclose on an annual basis any potential conflict of interest, including current or recent financial relationships with any commercial entity whose products or services may be contained in the journal content.
The following competing interests were disclosed:
Dr Robert Clarke
Dr Clarke is a paid consultant for ARNA Genomics, Inc, American Gene Technologies Inc and Bayer Pharmaceuticals.
Professor Antonio Di Cristofano
Professor Di Cristofano has received a grant from the NIH.
Dr Judith Favier
Dr Favier holds the patents 18,306,527.5 and EP2019/081848 on 'Methods for predicting metastatic potential in patients suffering from sdhb-mutated paraganglioma'.
Professor Paramita Ghosh
Professor Ghosh has paid grant review fees from National Institutes of Health, USA. She has research grants from National Institutes of Health, USA, Department of Veterans Affairs, USA, University of California, Davis, USA.
Professor Wouter de Herder
Professor de Herder has received speaker fees from Novartis-AAA, Pfizer and Ipsen, as well as financial research support from Ipsen and AAA-Novartis. He was the Chairman Educational Committee Dutch Society for Endocrinology and the Chairman EURACAN Domain 4 Neuroendocrine system from 2019 until present.
Professor Márta Korbonits
Professor Korbonits has received grant and consultancy fees from ONO, Crinetics, Novo & Ipsen.
Professor Deborah Marsh
Professor Marsh currently holds grants from the Australian Medical Research Future Fund (MRFF) and the Cancer Council NSW. She also has intellectual property that includes the following. Australian Patent No. 2010241416 entitled “Cancer Biomarkers”, published on 6th September, 2012 (Marsh and Hahn). European Patent No. 2638394 entitled “Histone protein ubiquitination as a cancer biomarker”, published 10/5/2017 (Marsh and Hahn). USA Patent Application No. 13/884733 “Cancer biomarkers” (filed, 10/5/2013 but not continued; Marsh and Hahn). Australian provisional patent application, “Selection methods for the treatment of cancer” (filed 9 October 2015), provisional patent application number 2015904120, the University of Sydney and Northern Sydney Local Health District (Shah, Marsh, Gard and Soon).
Professor Chris J McCabe
Professor McCabe has received honoraria from Novartis and Ipsen.
Dr Joanne Ngeow
Dr Ngeow is the recipient of research grants from AstraZeneca.
Professor Matthew D Ringel
Professor Ringel received honouraria fees for speaking at Laval University, Midatlantic Society of Endocrinology, Southern Society of Endocrinology, Virgina Commonwealth University, University of Connecticut, Internation Thyroid Cancer Congress (Sao Paolo). Advisory Board Chair, Children’s Hospital of Philadelphia and NIH study section reviewer.
Professor Constantine Stratakis
Professor Stratakis has Directorship of the new Research Institute, ELPEN SA, on genetics and personalized medicine. He has also received research funding from Pfizer, Inc. and Sterotherapeutics, LLC, as well as consulting fees for Sync, Inc. and Lundbeck pharmaceuticals. He holds patents on the function and/or mutations of the PRKAR1A, PDE11A and GPR101 genes.
The following editor reported no competing interests:
  • Professor Antonio Di Cristofano
Bioscientifica staff and freelancers working on the journal reported no conflicts of interest. Article authors' declarations are stated in each journal article. Referees must disclose any competing interests before agreeing to review any submission. For more information on the journal’s ethical policy, please read the ethical guidelines.
This policy follows the recommendations of the International Committee of Medical Journals Editors (ICMJE) and the Committee on Publication Ethics (COPE).